Role of Oral Microbiome Signatures in Diagnosis and Prognosis of Oral Cancer.


Journal

Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941

Informations de publication

Date de publication:
01 01 2019
Historique:
entrez: 3 8 2019
pubmed: 3 8 2019
medline: 23 2 2020
Statut: ppublish

Résumé

Despite advancement in cancer treatment, oral cancer has a poor prognosis and is often detected at late stage. To overcome these challenges, investigators should search for early diagnostic and prognostic biomarkers. More than 700 bacterial species reside in the oral cavity. The oral microbiome population varies by saliva and different habitats of oral cavity. Tobacco, alcohol, and betel nut, which are causative factors of oral cancer, may alter the oral microbiome composition. Both pathogenic and commensal strains of bacteria have significantly contributed to oral cancer. Numerous bacterial species in the oral cavity are involved in chronic inflammation that lead to development of oral carcinogenesis. Bacterial products and its metabolic by-products may induce permanent genetic alterations in epithelial cells of the host that drive proliferation and/or survival of epithelial cells.

Identifiants

pubmed: 31370775
doi: 10.1177/1533033819867354
pmc: PMC6676258
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1533033819867354

Références

Trends Immunol. 2014 Jan;35(1):3-11
pubmed: 24269668
Nat Rev Microbiol. 2005 Apr;3(4):343-9
pubmed: 15806096
Database (Oxford). 2010 Jul 06;2010:baq013
pubmed: 20624719
PLoS One. 2010 Dec 20;5(12):e15216
pubmed: 21188149
Oncotarget. 2015 Sep 8;6(26):22613-23
pubmed: 26158901
Biochem Biophys Res Commun. 2009 Feb 20;379(4):933-8
pubmed: 19138664
Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):391-6
pubmed: 19380363
Cell Host Microbe. 2013 Aug 14;14(2):195-206
pubmed: 23954158
Infect Immun. 2001 May;69(5):3431-4
pubmed: 11292769
DNA Cell Biol. 2009 Aug;28(8):405-11
pubmed: 19485767
Clin Exp Dent Res. 2018 Nov 28;4(6):255-262
pubmed: 30603107
Protein Cell. 2018 May;9(5):488-500
pubmed: 29736705
Oral Dis. 2017 Oct;23(7):926-940
pubmed: 28383789
Nat Rev Microbiol. 2019 Mar;17(3):156-166
pubmed: 30546113
Microbes Infect. 2008 Feb;10(2):122-8
pubmed: 18280195
Cell Microbiol. 2008 Apr;10(4):863-75
pubmed: 18005240
Biomed Pharmacother. 2016 Dec;84:552-558
pubmed: 27693964
Oral Dis. 2014 Jan;20(1):100-8
pubmed: 23444918
PLoS One. 2016 Jan 19;11(1):e0147039
pubmed: 26784334
J Clin Microbiol. 2006 May;44(5):1719-25
pubmed: 16672398
OMICS. 2016 Jan;20(1):3-11
pubmed: 26583256
J Support Oncol. 2006 May;4(5):252-8
pubmed: 16724649
J Oral Microbiol. 2016 Sep 26;8:32762
pubmed: 27677454
mBio. 2015 Feb 17;6(1):e01926-14
pubmed: 25691586
Theranostics. 2017 Sep 26;7(17):4313-4321
pubmed: 29158828
Front Microbiol. 2017 Mar 10;8:379
pubmed: 28344574
Oral Dis. 2005 May;11(3):151-6
pubmed: 15888105
Microbes Infect. 2000 Nov;2(13):1599-607
pubmed: 11113379
Carcinogenesis. 2018 May 28;39(6):778-787
pubmed: 29668903
Immunobiology. 2011 Dec;216(12):1302-10
pubmed: 21723642
J Transl Med. 2005 Jul 07;3:27
pubmed: 15987522
Technol Cancer Res Treat. 2017 Apr;16(2):150-158
pubmed: 27121074
Int J Cancer. 2019 Aug 1;145(3):775-784
pubmed: 30671943
Front Cell Infect Microbiol. 2017 Dec 01;7:493
pubmed: 29250491
Nat Rev Microbiol. 2018 Dec;16(12):745-759
pubmed: 30301974
Arch Oral Biol. 2003 May;48(5):329-36
pubmed: 12711376
Front Cell Infect Microbiol. 2017 Feb 24;7:57
pubmed: 28286742
Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2406-12
pubmed: 19745222
Genes (Basel). 2017 Mar 23;8(4):
pubmed: 28333122
Sci Rep. 2017 Jun 22;7(1):4036
pubmed: 28642609
Sci Rep. 2017 May 12;7(1):1834
pubmed: 28500338
J Dent Res. 2018 Jun;97(6):725-732
pubmed: 29630846
Front Immunol. 2012 Jan 12;2:98
pubmed: 22566887
Oral Dis. 2010 Nov;16(8):729-39
pubmed: 20646235
J Clin Microbiol. 2005 Nov;43(11):5721-32
pubmed: 16272510
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Curr Opin Microbiol. 2007 Feb;10(1):76-81
pubmed: 17208515
Infect Immun. 2011 Nov;79(11):4730-8
pubmed: 21859855
Front Microbiol. 2017 Nov 15;8:2244
pubmed: 29187843
Oral Oncol. 2018 Feb;77:1-8
pubmed: 29362114
Eur J Oral Sci. 2004 Oct;112(5):424-8
pubmed: 15458501
Trends Microbiol. 2002 Jun;10(6):293-9
pubmed: 12088666
J Med Microbiol. 2007 Dec;56(Pt 12):1651-9
pubmed: 18033835
Cancer Lett. 2017 Sep 28;404:1-7
pubmed: 28705771
Sci Rep. 2017 Nov 28;7(1):16540
pubmed: 29184122
Biomed J. 2016 Aug;39(4):251-260
pubmed: 27793267
Monogr Oral Sci. 2014;24:40-51
pubmed: 24862593
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Radiother Oncol. 2018 Oct;129(1):44-51
pubmed: 29735410
J Endotoxin Res. 2000;6(6):453-7
pubmed: 11521070
Future Microbiol. 2013 May;8(5):607-20
pubmed: 23642116
J Oral Maxillofac Surg. 2010 Jun;68(6):1270-5
pubmed: 20347201
Front Microbiol. 2018 May 03;9:862
pubmed: 29774014
J Dent Res. 2018 Apr;97(4):371-380
pubmed: 29195050
FEMS Immunol Med Microbiol. 2011 Apr;61(3):269-77
pubmed: 21205002
PLoS One. 2017 Sep 8;12(9):e0184515
pubmed: 28886168
Sci Rep. 2013;3:1843
pubmed: 23673380
Oncotarget. 2017 Oct 19;8(57):97273-97289
pubmed: 29228609
Oncotarget. 2016 Aug 9;7(32):51320-51334
pubmed: 27259999
Cell Microbiol. 2007 Aug;9(8):1997-2007
pubmed: 17419719
Sci Rep. 2016 Mar 10;6:22943
pubmed: 26961389
Oral Oncol. 1998 Jul;34(4):304-8
pubmed: 9813727
Biomed Pharmacother. 2017 May;89:918-925
pubmed: 28292019
Front Cell Infect Microbiol. 2018 Aug 03;8:267
pubmed: 30123780
Nat Rev Microbiol. 2010 Sep;8(9):623-33
pubmed: 20676145
J Pharm Bioallied Sci. 2017 Jul-Sep;9(3):155-163
pubmed: 28979069
Genome Med. 2017 Feb 7;9(1):14
pubmed: 28173873
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Int J Oral Sci. 2011 Oct;3(4):209-15
pubmed: 22010579
Cancer Epidemiol. 2015 Dec;39(6):923-38
pubmed: 26523982
Cell Microbiol. 2014 Jan;16(1):131-45
pubmed: 23991831
Appl Microbiol Biotechnol. 2016 Dec;100(23):10165-10177
pubmed: 27695967
J Transl Med. 2006 Mar 28;4:14
pubmed: 16566840
J Clin Periodontol. 2014 Nov;41(11):1037-47
pubmed: 25139209
ISME J. 2016 Oct;10(10):2435-46
pubmed: 27015003
Cancer Res. 2010 Feb 1;70(3):855-8
pubmed: 20086177
Mol Oral Microbiol. 2010 Apr;25(2):89-101
pubmed: 20331797
Int J Cancer. 2000 Nov 1;88(3):342-50
pubmed: 11054661
J Dent Res. 2017 Mar;96(3):292-299
pubmed: 27827319
Curr Oral Health Rep. 2015 Mar 1;2(1):48-56
pubmed: 26120510
Tumour Biol. 2014 Jul;35(7):7073-7
pubmed: 24756759
PLoS One. 2017 Feb 22;12(2):e0172196
pubmed: 28225785
PLoS One. 2014 Nov 20;9(11):e113385
pubmed: 25411778
Sci Rep. 2017 Sep 18;7(1):11773
pubmed: 28924229
PLoS One. 2010 Nov 03;5(11):e13826
pubmed: 21072208
Oral Oncol. 2009 Apr-May;45(4-5):454-60
pubmed: 18804412
J Bacteriol. 2010 Oct;192(19):5002-17
pubmed: 20656903
Oncotarget. 2017 Sep 7;8(67):110931-110948
pubmed: 29340028
BMC Microbiol. 2009 Dec 15;9:259
pubmed: 20003481
Tob Induc Dis. 2008 Dec 18;4:12
pubmed: 19094204
JAMA Oncol. 2018 Mar 1;4(3):358-365
pubmed: 29327043
J Oral Maxillofac Pathol. 2018 May-Aug;22(2):234-238
pubmed: 30158777
Microorganisms. 2019 Jan 13;7(1):
pubmed: 30642137
Sci Rep. 2017 Dec 15;7(1):17686
pubmed: 29247187
EBioMedicine. 2017 Apr;18:23-31
pubmed: 28216066
Int J Cancer. 2016 Oct 1;139(7):1512-9
pubmed: 27215979
Eur J Cancer Prev. 2015 Sep;24(5):373-85
pubmed: 25569450
Arch Oral Biol. 2018 Jun;90:45-52
pubmed: 29533791
PLoS One. 2014 Jun 02;9(6):e98741
pubmed: 24887397
BMC Oral Health. 2011 Dec 12;11:33
pubmed: 22152152
Oral Oncol. 2007 Feb;43(2):181-6
pubmed: 16859955
Trends Microbiol. 2017 May;25(5):362-374
pubmed: 28089325

Auteurs

Indranil Chattopadhyay (I)

1 Department of Life Sciences, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, India.

Mukesh Verma (M)

2 Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.

Madhusmita Panda (M)

1 Department of Life Sciences, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH